Calcineurin inhibitor minimization, withdrawal and avoidance protocols after kidney transplantation

Transplant International

Volumn 22, Issue 1, 2009, Pages 69-77

  Haller, Maria ^b   Oberbauer, Rainer ^a,b,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KH Elisabethinen ^*  (Austria)

^c Austrian Dialysis and Transplant Registry   (Austria)

Author keywords

Avoidance; CNI; Kidney transplantation; Minimization

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL PROTOCOL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW;

CALCINEURIN; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; PROTEIN KINASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 57349164961     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2008.00751.x     Document Type: Review

References (39)

1. Girlanda R, Kirk AD. Frontiers in nephrology: immune tolerance to allografts in humans. J Am Soc Nephrol 2007 18 : 2242.
2. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003 349 : 2326.
3. Rush D, Nickerson P, Gough J, et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998 9 : 2129.
4. Rush D, Arlen D, Boucher A, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. Am J Transplant 2007 7 : 2538.
5. Feutren G, Mihatsch MJ, Mihatsch MJ, International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 1992 326 : 1654.
6. Isnard BC, Tezenas du MS, Beaufils H, et al. Long-term renal effects of low-dose cyclosporine in uveitis-treated patients: follow-up study. J Am Soc Nephrol 2002 13 : 2962.
7. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999 397 : 530.
8. Chang SH, Russ GR, Chadban SJ, Campbell SB, McDonald SP. Trends in kidney transplantation in Australia and New Zealand, 1993-2004. Transplantation 2007 84 : 611.
9. Chapman JR, Marcen R, Arias M, Raine AE, Dunnill MS, Morris PJ. Hypertension after renal transplantation. A comparison of cyclosporine and conventional immunosuppression. Transplantation 1987 43 : 860.
10. Russ G, Jamieson N, Oberbauer R, et al. Three-year health-related quality-of-life outcomes for sirolimus-treated kidney transplant patients after elimination of cyclosporine. Transpl Int 2007 20 : 875.
11. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007 7 : 1506.
12. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007 356 : 2271.
13. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006 124 : 471.
14. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005 353 : 770.
15. Calne RY, White DJ, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978 5 : 1323.
16. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004 4 : 378.
17. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007 357 : 2562.
18. Flechner SM. A randomized, open-label study to compare the efficacy and safety of two different sirolimus (SRL) regimes with tacrolimus (TAC) + mycophenolate mofetil (MMF) in de novo renal allograft recipients: preliminary 2-year efficacy results from the ORION Trial. Am J Transplant 2008 8 (Suppl. 2 abs # 287, pp. 254.
19. Flechner SM. A randomized trial of sirolimus vs. cyclosporine in kidney transplantation: impact on blood cells, lymphocyte subsets, and flow crossmatches [abstract]. Am J Transplant 2002 2 (Suppl. 3 470.
20. Buchler M, Caillard S, Barier S, et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007 7 : 2522.
21. Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007 83 : 883.
22. Martinez-Mier G, Mendez-Lopez MT, Budar-Fernandez LF, et al. Living related kidney transplantation without calcineurin inhibitors: initial experience in a Mexican center. Transplantation 2006 82 : 1533.
23. Hazzan M, Buob D, Labalette M, et al. Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial. Transplantation 2006 82 : 657.
24. Ekberg H, Grinyo J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study. Am J Transplant 2007 7 : 560.
25. Abramowicz D, Manas D, Lao M, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 2002 74 : 1725.
26. Abramowicz D, Del Carmen Rial M, Vitko S, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005 16 : 2234.
27. Legendre C, Brault Y, Morales JM, et al. Factors influencing glomerular filtration rate in renal transplantation after cyclosporine withdrawal using sirolimus-based therapy: a multivariate analysis of results at five years. Clin Transplant 2007 21 : 330.
28. Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study. Transplantation 2005 79 : 446.
29. Gallagher MP, Hall B, Craig J, Berry G, Tiller DJ, Eris J. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 2004 78 : 1653.
30. Watson CJ, Firth J, Williams PF, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 2005 5 : 2496.
31. Schena F, Pascoe M, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24 months efficacy and safety results from the CONVERT trial. Transplantation (in press).
32. ANZDATA Registry Report 2007, Australian and New Zealand Dialysis and Transplant Registry. Adelaide, South Australia. http://www.anzdata.org.au
33. Pearson TC, Mulgaonkar S, Patel A, et al. Efficacy and safety of mycophenolate mofetil (MMF)/sirolimus (SRL) maintenance therapy after calcineurin inhibitor (CNI) withdrawal in renal transplant recipients: final results of the Spare-The-Nephron (STN) Trial. Am J Transplant 2008 8 (Suppl. 2 abs #129, pp. 213.
34. Servais A, Meas-Yedid V, Lebranchu Y, et al. Comparison at One Year of interstitial fibrosis (IF) by automatic quantification in renal transplant recipients with cyclosporine (CsA) discontinuation and sirolimus (SRL) introduction. Am J Transplant 2008 8 (Suppl. 2 abs #527, pp. 319.
35. Vitko S, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005 5 : 2521.
36. Lorber MI, Mulgaonkar S, Butt KM, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005 80 : 244.
37. Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 2004 78 : 1332.
38. Tedesco-Silva Jr. H, Vitko S, Pascual J, et al. A12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int 2007 20 : 27.
39. Baboolal K. A phase III prospective, randomized study to evaluate concentration-controlled sirolimus (rapamune) with cyclosporine dose minimization or elimination at six months in de novo renal allograft recipients. Transplantation 2003 75 : 1404.